Abstracts

Statin or ACE/ARB Effects on Neurocognitive Function of HIV-Infected Adults

Due to anti-inflammatory and anti-oxidant effects, we hypothesized that statins and angiotensin converting enzyme-inhibitors (ACE) or angiotensin-II receptor blockers (ARB) would protect neurocognitive function (NCF) among HIV+ adults on ART. Eligible participants from the ACTG ALLRT longitudinal cohort study were not on a statin or ACE/ARB within 30 days of first neurologic assessment (baseline), and…

Liver Fibrosis Linked to Cognition in HIV and HCV: The Women’s Interagency HIV Study

Cognitive disorders persist in up to one-half of people living with HIV despite access to combination antiretroviral therapy (cART). Minimal Hepatic Encephalopathy (MHE) occurs in cirrhotic patients with or without HIV infection and is thought to be associated with inflammation. Since HIV impairs gut barriers to pathogens, we hypothesized that HIV-infected adults are vulnerable to…

A Randomised Controlled Trial of Maraviroc-Intensified bPI ART on Cognitive Function

Maraviroc-intensified ART may have anti neuroinflammatory properties which could result in cognitive benefits. However intensified ART may be associated with increased neurotoxicity. Therapy naïve, neurologically asymptomatic, HIV-positive patients were randomly allocated on a 1:1 basis to a standard boosted-protease-inhibitor (bPI) ART regimen (Arm1; tenofovir-emtricitabine plus atazanavir/r) or a maraviroc 150mg once daily intensified bPI regimen…

Neurocognitive Safety After 96-WKs on ATV/r+3TC: Results of the Randomized SALT Trial

Due to its low CNS penetrance, there are concerns about the capacity of non-conventional ART to preserve neurocognitive performance (NP). The SALT study is a multicentre, open-label, non-inferiority clinical trial that compares whether 3TC+ATV/r (dual therapy; DT) is non-inferior to 2NRTI+ATV/r (triple therapy; TT), in HIV+ patients on a stable 3-drug regimen. The SALT NP…

Antiretroviral Use and Implications for DAA Therapy in HIV/HCV Coinfection

Interferon-free directly-acting antiviral (DAA) regimens for HCV provide a major advance in clinical management, including in HIV/HCV co-infection.  Drug-drug interactions (DDI) with combination antiretroviral therapy (cART) will require consideration.  The aim of this analysis was to characterise the cART regimens in HIV/HCV co-infected individuals and their suitability for co-administration with the following DAA HCV regimens:…

Interactions Between ABT-493 Plus ABT-530 Combination and Rilpivirine or Raltegravir

ABT‐493 (protease inhibitor discovered by AbbVie and Enanta) and ABT‐530 (NS5A inhibitor) are direct acting antivirals developed as a combination regimen for treatment of chronic hepatitis C virus genotype 1‐6 infection. Rilpivirine, a non‐nucleoside reverse transcriptase inhibitor (NNRTI), and raltegravir, a HIV‐1 integrase inhibitor are often used with other antiretroviral agents in the HIV‐HCV co‐infected…

Pharmacokinetics of Dolutegravir and Rilpivirine in Combination With SMV and SOF

Anti-HCV treatment with direct-acting antivirals (DAAs)-based regimens is a priority in HIV/HCV co-infected patients (pts) with advanced liver disease. We evaluated plasma through concentration of dolutegravir and rilpivirine (DTG-RPV) used in combination with simeprevir plus sofosbuvir (SMV-SOF) in HIV/HCV co-infected pts with advanced liver disease. Pts infected with HCV and HIV-1, with advanced liver disease…

Effect of Direct Acting Antivirals on the Pharmacokinetics of Calcineurin Inhibitors

Severe hepatitis C virus (HCV) recurrence affects post-transplant survival in HCV infected patients. We describe the effect of sofosbuvir-based anti-HCV therapy on disposition of anti-calcineurin immunosuppressive drugs. Liver transplant patients (pts) with severe HCV recurrence who signed the informed consent were included in the ANRS CO23 CUPILT cohort and their characteristics recorded. Immunosuppressive therapy backbone…